A phase 3, active (warfarin) controlled, double-blind, double-dummy, randomized study for assessing the efficacy and safety of rivaroxaban in patients with non-valvular atrial fibrilation

dc.contributor.advisor	Στεφανίδης, Ιωάννης Λ.	el
dc.creator	Καραγιαννίδης, Ευστράτιος	el
dc.date.accessioned	2017-04-26T09:09:49Z
dc.date.available	2017-04-26T09:09:49Z
dc.date.issued	2015
dc.identifier.other	14320
dc.identifier.uri	http://hdl.handle.net/11615/46172
dc.identifier.uri	http://dx.doi.org/10.26253/heal.uth.4432
dc.language.iso	en	en
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	en
dc.subject.other	Καρδιαγγειακό σύστημα -- Φάρμακα	el
dc.subject.other	Βιοστατιστική	el
dc.title	A phase 3, active (warfarin) controlled, double-blind, double-dummy, randomized study for assessing the efficacy and safety of rivaroxaban in patients with non-valvular atrial fibrilation	en
dc.type	masterThesis	en
heal.recordProvider	Πανεπιστήμιο Θεσσαλίας - Βιβλιοθήκη και Κέντρο Πληροφόρησης	el
heal.academicPublisher	Πανεπιστήμιο Θεσσαλίας. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής.	el
heal.academicPublisherID	uth	en
heal.fullTextAvailability	true	en
dc.rights.accessRights	free	en

Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International